SynteractHCR moves to expanded HQ in California after Amulet buyout

Comes after a new CEO and buyout deal this year

CRO SynteractHCR, bought by Amulet Capital Partners back in May and with a new CEO this summer, has seen another change-up as it moves its headquarters to larger digs.

The new facility in Carlsbad, San Diego County, sees it gain 38,000 square feet of space and has been designed with an “open concept to foster collaboration and creates a dynamic team environment, right in line with the company’s innovative business philosophy,” according to a statement from the company.

It also has offices in the Research Triangle Park area of North Carolina, the home of many top CROs, as well as 10 additional offices in Western, Central, and Eastern Europe.

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

SynteractHCR’s CEO Steve Powell, who took the helm of the CRO back in July after leaving Exco Intouch, said: “This move comes just one year after we doubled our space in Research Triangle Park and ensures we remain an important employer within the innovative local biotech and life science communities in San Diego, RTP and across the globe.

“The new Carlsbad space accommodates team members across all our core service offerings and is an important focus of operations for our experienced, knowledgeable staff of clinical development professionals. We look forward to hosting project teams and clients in this invigorating new environment.”

SynteractHCR was founded in 1995 and is now a top 20 full‐service CRO. It was since 2008 majority-owned by Gryphon Investors, a middle-market private equity firm based in San Francisco, before being bought out this year.

The company provides outsourced support to pharmaceutical companies, from drug development to marketing.

It has since grown further through acquisitions, with one of the biggest coming in 2013 when it acquired Germany’s Harrison Clinical Research—rebranding itself as SynteractHCR and expanding its reach to 16 countries.

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.